tirzepatide pulled from shelves GLP-1 Drugs: FDA Removes Lilly's Zepbound® and Mounjaro® (tirzepatide injection) its Drug Shortage List Zepbound Versus Wegovy: Head-to-Head Trial
Description
Chens team ran a pilot clinical study
The dual-incretin pharmacology is reported to produce additive effects on insulin secretion and glucagon suppression in preclinical metabolic research models
It is not approved for cellulite reduction or any cosmetic indications
That is larger than typical fluctuations because tirzepatide-driven metabolic changes amplify the hormonal effects on fluid balance
Pattern 4: significant regain after stopping or reducing tirzepatide Most likely cause: Loss of appetite suppression combined with metabolic adaptation and depleted lean mass
